Book a Meeting

Anti-CD47 Antibody, ADCC Enchanced (BioBet-CB-090LX) (CAT#: BioBet-CB-090LX) Datasheet

Target
CD47
Isotype
IgG4
Description
Anti-CD47 Antibody, ADCC Enchanced (BioBet-CB-090LX) is a glycosylation-modified anti-CD47 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD47 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD47
Full Name
CD47 molecule
Background
This gene encodes a membrane protein, which is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The encoded protein is also a receptor for the C-terminal cell binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This gene has broad tissue distribution, and is reduced in expression on Rh erythrocytes. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2010]
Alternative Names
CD47; CD47 molecule; IAP; OA3; MER6
Gene ID
961
UniProt ID
Q08722
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4
Antibody Clone
BioBet-CB-090LX
Host
Humanized
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human CD47 (Magrolimab) Antibody is derived from clone Magrolimab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD47, and it is intended for the research of Myelodysplastic syndromes .
Antibody Indication
Myelodysplastic syndromes

Myelodysplastic syndromes

Related Products

Anti-CD47 Antibody, Non-Fucosylated (MABL-1) (CAT#: BioBet-673ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.